Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 408 across all filing types
Latest filing 2024-11-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Korea Exchange regarding a 'Decision on Paid-in Capital Increase' (유상증자결정). This document details the issuance of new shares, the purpose of capital raising, the pricing methodology, and the third-party allocation details. This falls under the category of capital structure changes and financing activities.
2024-11-11 Korean
주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the acquisition of shares in another company (타법인 주식 및 출자증권 양수결정). This type of regulatory filing is a mandatory disclosure for material corporate events, such as M&A or significant asset acquisitions, which falls under the category of general regulatory filings in the absence of a more specific category like M&A (which usually refers to public takeover bids).
2024-11-11 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (cMET 표적항암제 바바메킵(ABN401)의 임상 2상 변경승인신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Abion) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding an application for a change in a clinical trial plan (Phase 2 for ABN401). Since this is a specific regulatory disclosure of a material event (clinical trial update) that does not fit into categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2024-11-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings for a specific individual (Hur Su young) at the company 'Abion'. This is a standard regulatory filing for insider trading or director/executive shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2024-11-07 Korean
투자판단관련주요경영사항(임상시험결과) (cMet 표적 항암제 바바메킵(ABN401)의 임상 1상 결과)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure filed by the company 'Abion' regarding the results of a Phase 1 clinical trial for their drug candidate 'vabametkib (ABN401)'. It follows the standard structure of a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a specific type of regulatory announcement in the Korean stock market (KRX) used to disclose material events such as clinical trial outcomes. Since it is a direct disclosure of material business information rather than a standalone audit report, investor presentation, or report publication announcement, it falls under the 'Regulatory Filings' category.
2024-11-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the change in share ownership by an executive (Lee Hwa Young) of the company Abion. This is a standard regulatory filing in South Korea (DART system) for reporting insider transactions or changes in holdings by directors and executives, which corresponds to the 'Director's Dealing' category.
2024-11-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.